financetom
Business
financetom
/
Business
/
BOJ to cut growth, inflation forecasts as pandemic pain persists: Sources
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
BOJ to cut growth, inflation forecasts as pandemic pain persists: Sources
Oct 20, 2020 2:35 AM

Japan’s central bank is expected to cut its growth and price forecasts for the current fiscal year at next week’s rate review, sources familiar with its thinking said, as the coronavirus pandemic weighs on the economic recovery. But any such downgrade is unlikely to trigger an immediate expansion of monetary stimulus, with the Bank of Japan expected to maintain its assumption that the world’s third-largest economy will post a moderate pick-up, the sources said.

Share Market Live

NSE

”It’s somewhat weaker than three months ago,” one of the sources said of this fiscal year’s growth projections, a view echoed by two other sources.

The main reason for the downward revision in growth is the bigger-than-expected economic slump in April-June and soft consumption during the summer, the source said.

”Risks are skewed to the downside,” a second source said, adding that weak service-sector spending and prospects of deeper cuts in capital expenditure cloud the outlook.

In the most recent projection made in July, the BOJ expects the economy to contract 4.7% in the current fiscal year ending March 2021. That is less pessimistic than a 6.0% fall projected in this month’s Reuters poll.

The BOJ’s July forecasts were compiled before the release of data that showed Japan’s economy shrank an annualised 28.1% in April-June, its worst postwar slump.

The nine-member board is also seen slightly trimming its inflation forecast for the current fiscal year, due largely to the impact of a government campaign offering discounts for domestic travel, the sources said.

The BOJ’s current projection is for core consumer prices to fall 0.5 percent this fiscal year.

The central bank is widely expected to keep monetary policy steady at the rate review on Oct. 28-29, when it will also release the fresh quarterly growth and inflation projections.

The board is unlikely to make major changes to its growth and price forecasts for fiscal years ending March 2022 and 2023, the sources said.

The sources spoke on condition of anonymity due to the sensitivity of the matter.

SUFFICIENT FRAMEWORK

Japan’s economy is gradually emerging from the second quarter’s steep slump, with exports and output picking up thanks to a rebound in automobile sales and China’s solid recovery.

But domestic demand remains soft with household spending falling for an 11th straight month in August as declining wages keep consumers’ purse strings tight.

Big firms plan to raise capital spending by just 1.4 percent in the current business year, a quarterly BOJ survey showed in October, lower than a 3.2 percent increase projected in June. Many BOJ officials expect firms to cut spending plans further in the coming months, as the pandemic hits profits. Resurgent infections in Europe add to uncertainty for the export-reliant economy, the sources said.

Despite the risks, the BOJ is in no mood to ramp-up stimulus now having eased policy in March and April, they said.

Under a framework created to cushion the blow from the pandemic, the BOJ now buys huge sums of government and private debt. It also offers incentives to financial institutions that boost lending to smaller firms hit by the crisis.

That framework is the first line of defence against new strains on the economy caused by the pandemic, the sources said, suggesting that other steps such as interest rate cuts will be considered only in more extreme circumstances.

Under a policy dubbed yield curve control, the BOJ sets interest rates as its main policy target. It now pledges to guide short-term rates at -0.1% and 10-year yields around zero.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Once a beacon of stability, Vietnam to name third president in a year
Once a beacon of stability, Vietnam to name third president in a year
Mar 22, 2024
HANOI, March 22 (Reuters) - Communist-ruled Vietnam is seeking its third president in little more than a year after the resignation of Vo Van Thuong, who was only elected last year after the sudden dismissal of his predecessor. With accumulated foreign direct investment higher than its gross domestic product, Vietnam's stability is crucial to multinationals with large operations in the...
Japan's union group Rengo announces biggest wage hikes on record
Japan's union group Rengo announces biggest wage hikes on record
Mar 22, 2024
TOKYO (Reuters) -Japanese firms have agreed to raise pay by 5.25% this year, the biggest rise under comparable data since 2013, the country's largest union group Rengo confirmed on Friday. The results of the closely-watched wage negotiations are announced in several stages, in which the blue-chip firms are first to wrap up their talks in mid-March. The second announcement on...
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Mar 22, 2024
(Reuters) - Popular investor Cathie Wood's ARK Invest bought nearly 10,000 shares of Reddit ( RDDT ) in the social media platform's strong market debut on Thursday, an email from the asset manager showed. A total of 9,982 shares of the loss-making company was added to ARK Next Generation Internet ETF ( ARKW ) and ARK Fintech Innovation ETF (...
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Mar 22, 2024
05:04 AM EDT, 03/22/2024 (MT Newswires) -- Hutchmed ( HCM ) said late Thursday it has started the registration stage for a phase 2/3 clinical trial of investigational drug sovleplenib for adult patients with warm antibody autoimmune hemolytic anemia in China. The move follows positive data from the proof-of-concept phase 2 stage of the trial and a consultation with the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved